EGLN1 and anemia (phenotype): Previous PHD2 inhibitor drugs target the catalytic pocket28, Rox (IC50 = 117.2 nmol/L), Vad (IC50 = 256.9 nmol/L) and Dap (IC50 = 140.8 nmol/L), primarily targeted the HIF-1α signaling pathway to stabilize HIF-α and enhance EPO expression, mainly for conditions such as anemia.